|
|
||||||||
Clinical Overview |
Moluk Mirrasouli Ragland, DO, Department of Medicine, University of North Texas Health Science Campus, 855 Montgomery Road, 4th Floor, Fort Worth, Texas 76107
Tahir Tak, MD, PhD, Department of Medicine, University of North Texas Health Science Campus, 855 Montgomery Road, 4th Floor, Fort Worth, Texas 76107
Reprint Requests: Tahir Tak, MD, PhD, Department of Medicine, University of North Texas Health Science Center, 855 Montgomery Road, 4th Floor, Fort Worth, Texas 76107, Tel: 817-735-2332; Fax: 817-735-2673, E-mail: ttak{at}hsc.unt.edu
Received: August 18, 2005.
Revised: November 30, 2005.
Accepted: December 13, 2005.
| Abstract |
|---|
|
|
|---|
Key Words: Cardiac neoplasms Diagnostic imaging Echocardiography Magnetic resonance Imaging Tomography
The first effort to use pulse-reflected ultrasound to examine the heart was initiated by Dr. Helmut Hertz of Sweden in collaboration with Dr. Inge Edler.1 Despite their initial efforts at using ultrasound to examine the heart, neither Edler nor Hertz really anticipated that this technique would develop as rapidly as it did.1 In the 1950s, Dr. Effert and his colleagues in Germany began to duplicate Edlers work describing mitral stenosis. During their work, Effert and his group detected left atrial masses. Since the initial ultrasonographic demonstration of an atrial myxoma by Effert and Domanig in 1959, the value of echocardiography for diagnosing cardiac mass lesions has become well established.2 Numerous advances have occurred in the last five decades. The evolution of echocardiography involves the development of its many modalities of A-mode, M-mode, contrast echocardiography, two-dimensional echocardiography (2DE), Doppler ultrasound, transesophageal echocardiography (TEE) and intravascular applications.1 In this review, we describe various cardiac masses and the role of 2DE in the evaluation of these space-occupying lesions. A discussion and review of other imaging modalities, such as computed tomography (CT) and magnetic resonance imaging (MRI), are also presented.
| Structures Misinterpreted for Cardiac Masses |
|---|
|
|
|---|
|
|
In addition to normal variants and echocardiographic artifacts, extracardiac masses may compress the heart and create a mass effect. Examples of such masses (pseudotumors) include mediastinal tumors, coronary aneurysms or hiatal hernias.1 An example of a hiatal hernia that shows a herniated portion of the stomach appearing as a mass within the atrium is shown in figure 2
. The diagnosis of hiatal hernia can be verified by having the patient drink a carbonated beverage during the transthoracic echocardiographic (TTE) examination.1
|
| Primary Cardiac Tumors |
|---|
|
|
|---|
|
| Benign Cardiac Tumors |
|---|
|
|
|---|
|
Two-dimensional echocardiography is the imaging modality of choice, classically revealing a mobile tumor connected to the interatrial septum by a narrow stalk.5 Myxomas usually have heterogeneous echogenecity and occasional calcifications. The most important clue to the diagnosis is their location in the left atrium and origin from the mid-portion of the atrial septum.1 It is, therefore, important to identify the site of tumor attachment during the echocardiographic examination. This allows us to differentiate it from other masses, e.g., a thrombus. Given a typical presentation, echocardiography is virtually diagnostic of myxoma.1 TTE is usually sufficient to make the diagnosis, but if the results are suboptimal, TEE should be employed.5 Investigations have shown that MRIs and CT scans have no incremental value in diagnosing cardiac myxoma when the echocardiography is of good quality and identifies the tumor and its site of attachment. The thin, delicate stalk of myxoma usually cannot be defined at CT or MR imaging.11 Although a generally narrow base of attachment can be seen on CT and MRI, it is suggestive of, but not definitive for, a diagnosis of myxoma.11
Familial myxomas constitute 10% or less of all myxomas.5 In contrast to sporadic myxomas, which typically present at an older age, patients with familial myxoma tend to present earlier (median age, 20 years) and are more likely to have myxomas in atypical locations, to have multiple tumors, are more likely to develop recurrent tumors, and have associated dermatological and endocrine abnormalities.13 Vidaillet et al.13 described these distinctive clinical features of familial myxoma as "syndrome myxoma," which is also known as "Carney complex" of myxomas, spotty skin pigmentation and endocrine overactivity. A careful search for multiple cardiac tumors should be made to differentiate sporadic from familial myxomas. Due to the autosomal dominant transmission of Carney complexes, identification of multiple cardiac myxomas in a young individual should prompt echocardiographic screening of first-degree relatives.14 Postoperatively, these patients should be observed closely for recurrence of myxomas due to a recurrence rate of 12% to 22%.5
Lipomas
Lipomas are the second most common benign cardiac tumors (with a frequency of 10% of benign cardiac tumors)1 and are usually seen in the left ventricle, right atrium and interatrial septum.5 About 50% arise subendocardially, 25% subepicardially and 25% from the myocardium.12 Their size can range from 1 cm to 15 cm.
Echocardiography typically reveals a homogenenous, hyperechoic mass, but these findings are not diagnostic.5 The echocardiographic appearance of lipomas can vary depending on their location. Lipomas in the pericardial space are usually hypoechoic, whereas intracavitary lipomas are homogenous and hyperechoic.11 The etiology for these findings is not known. Since both CT and MRI can help identify fat with a high degree of specificity, they can be used to diagnose cardiac lipomas without equivocation.11 For this reason, reports of cardiac lipomas over the past 10 years to 15 years have tended to emphasize the role of CT and MRI.11 Studies have shown that the best imaging modality is MRI.5 On MRI, lipomas have homogeneous increased signal intensity on T1-weighted images that decrease with fat-saturated sequences.11
Lipomatous hypertrophy (mentioned earlier under normal variants) is often discussed with cardiac lipomas, but it does not constitute a true neoplasm. It is thought to be benign and rarely associated with clinical manifestations.1 In contrast to true cardiac lipomas that can occur at any age, lipomatous hypertrophy of the interatrial septum is seen in obese and relatively older patients.11 Lipomatous hypertrophy has a reported incidence of 1% to 8% and is usually an incidental finding because most patients with this condition are asymptomatic.4 Patients with lipomatous hypertrophy are generally obese and may be difficult to image with conventional TTE.15 TEE can provide high quality imaging in these patients and shows the classic dumbbell or hourglass appearance of septum caused by fatty infiltration of the proximal and distal portions of the septum with sparing of the fossa ovalis area (figure 1B
).4
Papillary fibroelastoma
Papillary fibroelastomas are small tumors (
1 cm) that account for approximately 8% of primary benign cardiac tumors.1 They are usually found in older patients with the average age at detection of 60 years.5 They commonly arise on the mitral and, less commonly, on the aortic valve, but can also be found on other endocardial surfaces (figure 3B
). Due to their small size, generally 0.5 cm to 2.0 cm in diameter, and their occurrence on the valves, they may be difficult to distinguish from valvular vegetations. However, unlike vegetations, fibroelastomas are more often found on the downstream side of the valve, and despite their valvular attachment, valvular dysfunction is uncommon.5 If valvular dysfunction (valvular destruction or regurgitation) is present, valvular vegetations rather than papillary fibroelastoma should be suspected. A characteristic shimmer or vibration at the tumor-blood interface, ascribed to the finger-like projections of the tumor, has been described and is best appreciated on TEE.5 There is some confusion as to whether fibroelastomas are distinctly different from Lambls excrescences, which are smaller in size and seen more frequently in elderly patients.1 Lambls excrescences are usually along the closure margins of the valve cusps (figure 3C
).
Papillary fibroelastomas are friable tumors that are likely to form surface thrombus and have the potential to embolize.16,17 Anticoagulation does not appear to protect against these embolic events.5 Surgical treatment (especially of left-sided lesions) has been described in cases where there has been recurrence of strokes, presumably secondary to embolism.5
Rhabdomyoma
Rhabdomyomas have a frequency of approximately 6% of all benign tumors and commonly occur in infants and children.1 Approximately three-fourths occur in patients younger than 1 year and are extremely uncommon in the adult patient.5,18 They occur either within a cavity, sometimes as a pedunculated mass, or embedded within the myocardium (figure 3D
). Such tumors can grow quite large and obstruct blood flow within the heart.1 They occur with equal frequency in the right and left ventricular and septal myocardium, can involve either one or both atria, and nearly all are multiple.5 The type and severity of symptoms depend on the location and size of the tumors. Heart block is the most common manifestation, but paroxysmal supraventricular tachycardia, ventricular tachycardia and sudden cardiac death have also been reported.5 Intracavitary tumors may lead to signs and symptoms of congestive heart failure secondary to obstruction of blood flow.5 Rhabdomyomas are strongly associated with tuberous sclerosis, which is an autosomal dominant syndrome characterized by hamartomas in several organs, epilepsy, mental deficiency and adenoma sebaceum. Several studies show that at least 80% of patients with cardiac rhabdomyomas have tuberous sclerosis.5 However, cardiac rhabdomyomas in tuberous sclerosis patients is often present without major arrhythmia or hemodynamic obstruction.19 Before the advent of echocardiography, the majority of published reports about cardiac rhabdomyoma were based on autopsy studies.19 Echocardiography is usually adequate for diagnosis and typically reveals multiple small, lobulated, homogeneous, hyperechoic intramural tumors.5 Prognosis of asymptomatic patients is usually excellent, however, children with symptomatic cardiac rhabdomyoma have a poor prognosis. It has been reported that 78 % of children with symptomatic rhabdomyoma died before the age of 1 year.19 Fortunately, 50% or more of rhabdomyomas regress spontaneously after infancy and even resolve completely without the need for intervention.18 Thus, in the absence of symptoms, surgery is not indicated. In a study that aimed to investigate the mechanism of spontaneous tumor regression, it was concluded that the cytoplasmic content in cardiac rhabdomyoma were degraded via ubiquitin pathway and the rate of cell death was increased in cardiac rhabdomyoma.20 If rhabdomyomas are confirmed with biopsy, the patient should be followed up with periodic echocardiograms rather than surgery.5 Surgery is reserved for symptomatic patients with significant hemodynamic obstruction.19 Even if surgery is indicated, complete removal of cardiac rhabdomyomas is not always possible because these tumors are usually located deep in the myocardium. However, limited surgical excision is often effective because the residual tumor usually involutes.19
Fibromas
Fibromas are uncommon benign tumors that are most often seen in children (second most common benign pediatric cardiac tumor) but are rare in adults.3,21 They are usually found in the ventricular myocardium and usually occur within the left ventricular free wall, anterior free wall or the interventricular septum.21 They vary in size from 3 cm to 10 cm and have central calcifications. On echocardiography, they appear as distinct, highly echogenic and well-demarcated masses that often extend into the cavity of the ventricle.1 They may be confused with rhabdomyomas. Although benign, they occasionally result in obstruction to left ventricular filling and have been associated with ventricular arrhythmias.1 Like lipomas, they are not associated with systemic embolization.
There is an increased prevalence of cardiac fibromas in Gorlin syndrome, also known as nevoid basal cell carcinoma syndrome. The incidence of this autosomal dominant syndrome is uncommon, but not rare and it is marked by different signs at different ages, making recognition difficult.21 It is associated with basal cell carcinoma, odontogenic keratocysts of the mandible, skeletal anomalies and a tendency toward neoplastic growth in several organ systems.11 Gorlin syndrome is characterized by skeletal (spine and rib) abnormalities, calcification of the falx cerebri (strongly suggestive of this syndrome), multiple basal cell carcinomas (the hallmark of this syndrome), small palmar or plantar pits due to superficial keratin defects and multiple jaw keratocysts (often the initial sign of the syndrome).21 Both cardiac and ovarian fibromas have been associated with this syndrome.22 Cotton et al21 describe a case report of a 2-year-old child with a cardiac fibroma that was subsequently diagnosed as having Gorlin syndrome. Based on these findings, it is recommended that patients with a nevoid basal cell carcinoma be evaluated for cardiac fibromas. Echocardiography typically reveals an intramural, homogeneous, echogenic mass.5 Approximately 70% of fibromas are symptomatic, causing mechanical interference with intracardiac flow, ventricular systolic function or conduction disturbances. Sudden cardiac death occurs in 14% of patients with fibromas, typically in infants.5 Cardiac fibromas are often associated with arrhythmias and are the second most common primary cardiac tumor associated with sudden death after endodermal heterotopia of the atrioventricular node.11 Given the risk of fatal arrhythmias, resection is usually recommended even in asymptomatic cases. Other rare benign tumors include teratoma (which occurs mostly in infants), hemangioma and mesothelioma.3
| Malignant Cardiac Tumors |
|---|
|
|
|---|
Angiosarcomas
Angiosarcomas are the most common primary malignant cardiac tumors accounting for 30% of primary cardiac sarcomas.5 They commonly occur in middle aged men.24 These tumors have a striking predilection for the right atrium and may be either intracavitary and polypoid or diffuse and infiltrative.5 Angiosarcomas have a nonspecific clinical course and physical examination, and are usually diagnosed postmortem.25 Although clinical presentation is often nonspecific, recurrent unexplained pericardial effusion is a common manifestation and should raise a high index of suspicion.24 However, even if diagnosis is made promptly, the majority of patients already have metastasis at the time of discovery. The prognosis of cardiac angiosarcoma is notoriously grave, with a median survival time of 3 to 6 months.24
Rhabdomyosarcomas
Embryonal rhabdomyosarcomas account for 10% of all primary cardiac sarcomas, but are the most common cardiac malignancy in infants and children.5 They usually arise from the ventricular walls and frequently interfere with valvular motion because of their intracavitary bulk.7 The right atrium is involved most often, where the appearance can resemble myxoma.3 Other less common malignant tumors consist of various sarcomas: myxosarcoma, liposarcoma, fibrosarcoma, leiomyosarcoma, osteosarcoma, synovial sarcoma, undifferentiated sarcoma, reticulum cell sarcoma, neurofibrosarcoma and malignant fibrous histiocytoma.26
Primary cardiac lymphoma
Lymphomas account for 5% of primary malignant cardiac tumors.5 Overall, however, they are extremely rare and represent only 1% of all (benign and malignant) primary cardiac tumors.27 Primary cardiac lymphoma is defined as an extranodal non-Hodgkins lymphoma involving only the heart and pericardium at the time of diagnosis.27 Lymphomatous involvement of the heart and/or pericardium usually occurs by dissemination, and cardiac involvement as the initial presenting manifestation of malignant non-Hodgkins lymphoma is extremely rare. Nevertheless, its frequency has been increasing in the past 10 years, mainly in immunocompromised patients.27 Clinical presentation of primary cardiac lymphoma varies, is nonspecific and depends on which cardiac structures are involved. Patients may present with congestive heart failure, arrhythmias, pericardial effusion or superior vena cava syndrome.27 Diagnostic techniques such as electrocardiography, echocardiography, CT and MRI are nonspecific for lymphoma and confirmation of the diagnosis requires morphological examination of the tissue infiltrated by the tumor. A method with high diagnostic accuracy is necessary to ensure successful therapy for primary heart lymphoma.27 Since cytological examination of pericardial fluid is not always sensitive for malignancies, especially for lymphoma, and not all patients are compromised by the pericardial effusion, a transvenous biopsy of the tumor is preferred.27 Transvenous biopsy has been used successfully to diagnose cardiac lymphomas and is well established for obtaining adequate diagnostic tissue particles.27
The prognosis of primary heart lymphoma is poor due to diagnostic delay and advanced stage of organ infiltration.27 The survival is generally less than a month without treatment, but has been prolonged to up to 5 years with chemotherapy and radiation therapy in selected cases.28
| Metastatic Tumors of the Heart |
|---|
|
|
|---|
| Intracardiac Thrombi |
|---|
|
|
|---|
|
Compared to other diagnostic procedures, MRI and CT offer a similar sensitivity of about 90%, with a slightly better specificity as compared to 2DE.12 Spontaneous echo contrast (SEC), or "smoke," is the swirling, hazy echocardiographic appearance associated with low blood flow.1 Several investigators consider SEC to be a pre-thrombotic condition, although it is not clearly established that SEC actually leads to thrombus formation.1 Regardless of the cause and effect, the presence of SEC has been consistently associated with increased risk of thromboembolism.1
| Clinical Value of Common Imaging Modalities Utilized for Evaluation of Cardiac Masses |
|---|
|
|
|---|
Although echocardiography has many advantages for evaluating cardiac tumors, there are some limitations. Bone and lung interference remains a major limitation of echocardiography and renders this real-time imaging technique suboptimal in patients with chronic obstructive pulmonary disease or narrow rib spaces.33 Aside from suboptimal image quality in some patients, echocardiography has limited field of view compared to MRI and CT (discussed later). TEE can provide further information when limited acoustic viewing restricts optimal evaluation. In one study of 17 patients investigated for cardiac tumor, TTE showed 4 false-positives and 2 false-negatives, whereas TEE resulted in only 1 false-positive and no false-negatives.3 Thus, TEE has superior specificity and sensitivity for diagnosing cardiac tumors.3 The potential advantages of TEE include improved resolution of the tumor and its attachment, the ability to detect some masses not visualized by TTE and improved visualization of right atrial tumors.5 Both TEE and TTE are equally effective in visualizing tumors originating from the heart. However, when comparing TTE with TEE in patients with mediastinal tumors, marked differences were seen.34 Tumors originating from the mediastinum were 2.9 times less likely to be detected by TTE than TEE, and TEE was also superior in diagnosing tumor infiltration and invasion of the heart and the great vessels.34 In patients with malignant tumors originating in the heart, TEE provided superior information to the TTE approach regarding the site of attachment, intra- and extracardiac expansion and the morphological characterization of the tumor surface.34 The sensitivity of these criteria for identifying patients with histologically proven malignant tumors was only 8% when the transthoracic approach was used, but increased to 40% using transesophageal imaging.34 In conclusion, although TEE appears to be superior to TTE in many patients, it is not warranted on a routine basis and should be considered when the transthoracic study is suboptimal or where TTE is impossible (e.g., during surgery).5,35
Echocardiographic contrast perfusion imaging has been used to characterize vascularity of cardiac masses and differentiate malignant/highly vascular tumors from benign tumors and thrombi. Since most benign cardiac tumors are relatively avascular, the vascularity of a mass may be a feature that can help differentiate benign from malignant tumors.36 In the study by Kirkpatrick et al37 echocardiographic contrast perfusion imaging showed that compared with the adjacent myocardium, malignant and vascular tumors hyper-enhance, whereas stromal tumors and thrombi hypo-enhance. Malignant or highly vascular tumors demonstrated greater enhancement than the myocardium, myxomas (which have a poor blood supply) demonstrated less perfusion than myocardium and thrombi (generally avascular) demonstrated no perfusion.37 In the past, CT scans could not define intracardiac anatomy because of long scan times relative to cardiac and respiratory motion. Recent advances in CT have greatly improved its application to cardiac imaging. Of note, data acquisition is sufficiently rapid (50 to 100 msec) for electron beam tomography (EBT) that cardiac gating is not absolutely necessary, permitting adequate imaging in patients with irregular rhythms.5 CT provides a high degree of soft tissue discrimination, which is helpful in defining the degree of myocardial infiltration.5 It appears to be useful to determine the degree of myocardial invasion and involvement of extracardiac structures in patients with suspected malignancy of the heart because it allows evaluation of extracardiac structures. Mousseaux et al38 demonstrated that EBT provides additional anatomical information over cross-sectional echocardiography in all patients with malignant tumors and it provides better delineation of the relation between intracavity masses and normal structures, including the mural site of attachment and tumor extensions. On the other hand, EBT provides no additional information over cross-sectional echocardiography in patients with myxomas, thus cross-sectional echocardiography alone is sufficient to establish the need for surgery.38 In 70% of the cases studied by Mousseaux et al38 EBT modified the diagnosis or confirmed a diagnosis that had been questionable by cross-sectional echocardiography. Gross et al39 demonstrated that CT evaluates extent of disease, including invasion of contiguous vessels and pulmonary metastases, better than echocardiography. Furthermore, CT was able to directly image neoplastic pulmonary emboli.39 CT can also be used to assess for calcification, which may be useful in the diagnosis of rhabdomyomas, fibromas, teratomas, myxomas, hemangiomas and osteosarcomas.5 Although CT has some advantages over echocardiography, it is more invasive because it requires the use of ionization radiation and frequently an intravascular injection of contrast medium.33 This limits the use of contrast CT in patients with compromised renal function.
MRI is also useful in evaluation of cardiac masses. MRI can be used to verify intracardiac masses found on 2DE and to exclude a mass when the echocardiogram is equivocal.40 MRI can provide information about tissue composition of cardiac masses when images are obtained with pulse sequences of different T1 and T2 weightings.41 T1-weighted and T2-weighted dual-inversion recovery fast spin-echo sequences offer detailed morphological information, with T1-weighted images providing excellent soft tissue characterization and T2-weighted images providing superior tissue contrast and demonstration of fluid components.5
MRI allows this tissue characterization by comparing the T1 and T2 values of the masses to a reference tissue, which is fat.12 Tissue characterization by MRI is limited to the diagnosis of myxomas, fibromas, thrombi and fatty tissue.12 The signal features of malignant tumors are ambivalent and do not permit a tissue diagnosis.12 The primary contribution of MRI is not the ability to obtain tissue diagnosis, but rather its ability to delineate the anatomic extent and to aid in treatment planning.42 In addition to having a large field of view that allows imaging of the paracardiac space and the great vessels, MRI enables high-resolution tomography in three dimensions, is nonionizing and generates intravascular and soft tissue contrast without the need for contrast medium.33,43 Amparo et al44 demonstrated that MRI could provide as useful information as echocardiography, CT and angiography combined in the evaluation of cardiac and paracardiac masses. However, considering the expense, it is not cost effective. Furthermore, unlike echocardiography, MRI cannot be brought to the bedside. Additionally, use of MRI is contraindicated in patients with cardiac pacemakers, implanted defibrillators and other similar mechanical devices.
Both CT with MRI allow imaging and evaluation of extracardiac structures. Comparing CT and MRI, CT is faster and easier to perform, while MRI provides better soft-tissue contrast and allows much greater flexibility in the selection of imaging planes.11 Another difference is that calcium cannot be identified by MRI and when calcification of a mass is suspected, CT offers a distinct advantage over the other modalities.11,33
| Conclusion |
|---|
|
|
|---|
Three-dimensional echocardiography is a useful tool that may provide additional information or better visualization of intracardiac masses.46,47 It is conceivable that echocardiography will continue to evolve and play a prominent role in clinical medicine and that improvements in technology will likely provide better images and diagnostic information in the future.
| References |
|---|
|
|
|---|
This article has been cited by other articles:
![]() |
K. Tasdemir, B. Sarli, M. G. Kaya, and O. Gunebakmaz Mobile biatrial thrombus in a patient with mitral stenosis under heparin infusion Interactive CardioVascular and Thoracic Surgery, August 1, 2008; 7(4): 667 - 669. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. N. Lysitsas, P. Banerjee, and M. F. Shiu Cardiac tamponade because of left atrium direct invasion by a large cell neuroendocrine metastatic carcinoma of the lung Eur J Echocardiogr, May 1, 2008; 9(3): 428 - 429. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. E. Moustafa, C. Sauve, and R. Amyot Assessment of a right ventricular metastasis using contrast echocardiography perfusion imaging Eur J Echocardiogr, March 1, 2008; 9(2): 326 - 328. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |